Scotland Backs Bispecific Antibody for Refractory Myeloma

by | Jun 10, 2026 | Health

Spread the love
The SMC accepted talquetamab for relapsed and refractory multiple myeloma, offering eligible patients in Scotland a new option after multiple prior therapies.
Medscape News UK

Written By

Written by Albert Pham, News Curator and Blogger

Related Posts

0 Comments